- Home
- OMH vs PPBT Comparison
OMH vs PPBT Comparison
Compare OMH & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OMH | PPBT |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 3.8M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OMH | PPBT |
|---|---|---|
| Price | $1.20 | $4.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 22.5K | 8.3K |
| Earning Date | 04-28-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.41 |
| 52 Week High | $4.33 | $5.18 |
Technical Indicators
Market Signals| Indicator | OMH | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 62.46 |
| Support Level | $1.08 | $3.63 |
| Resistance Level | $1.38 | $5.18 |
| Average True Range (ATR) | 0.07 | 0.33 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 31.03 | 67.08 |
Price Performance
Historical ComparisonAbout OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.